Latest Blood disorders Stories
A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes(CN-AML). The study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) found that when microRNA-3151 (miR-3151) is overexpressed in CN-AML, the disease responds poorly to...
Rituximab seems to only help cases that respond to standard therapies Highlights: Children with a particular kidney immune disorder that is unresponsive to standard treatments do not benefit from the immune drug rituximab. Additional studies are needed to fully understand the disease and to develop effective therapies for hard-to-treat cases. The drug rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis, has...
SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri® (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting. (Photo:...
SUNNYVALE, Calif., May 10, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal third quarter ended March 31, 2012. Financial Results for Third Quarter Ended March 31, 2012 The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fiscal quarter ended March 31, 2012 was $9.3 million, or $0.14 loss per share. This compares with a non-GAAP net loss of $7.4 million, or $0.12 loss per...
WHITE PLAINS, N.Y., May 9, 2012 /PRNewswire/ -- Actress and singer-songwriter Miranda Cosgrove has been named The Leukemia & Lymphoma Society's National Ambassador for its 2012 Light The Night® Walks and appears in a new public service announcement to promote this important fundraising campaign. "I will walk for my grandmother in hopes of a healthy recovery," said Cosgrove. "I will walk for my fans -- those teens who have battled leukemia -- the most common cancer in teens...
Children's Hospital of Philadelphia researcher finds pathway driving cancer signals Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma. B cell lymphomas,...
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical College provide the very first long-term outcome data for...
WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical...
CHICAGO, May 4, 2012 /PRNewswire/ -- Data presented today by CSL Behring at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (i.e., warfarin). Currently in the United States, fresh frozen plasma is the standard treatment for warfarin reversal. The data are from the...
AMSTERDAM, May 4, 2012 /PRNewswire/ -- - 2nd Invitation to 17th Congress of EHA - European Hematology Association The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 17th Congress of EHA. More than 9,000 participants from around the world are expected at the upcoming Congress at the RAI Congress Center in Amsterdam from June 14-17, 2012. About the EHA Annual Congress: The...
